Jun 10, 2021 / 01:40PM GMT
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone, and thank you for joining us. My name is Nathan Rich, and I cover the animal health space here at Goldman. We're very pleased to introduce our next session with Elanco Animal Health. We're joined by the company's President and CEO, Jeff Simmons.
Before we jump into the Q&A, I just wanted to remind everyone on the webcast (Operator Instructions)
And with that, Jeff, thanks so much for your time, and thanks for joining us today.
Questions and Answers:
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research AnalystMaybe to start at a high level, if you could just summarize for investors, the company's in December issued guidance for 3% to 4% annual revenue growth and working towards an EBITDA margin of 31% by 2024. If achieved, that would significantly improve the company's financial profile over the next 3 years.
I guess to start, what are the key priorities, in your view, that the business needs
Trustpilot
